• 1
    Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982;217:9981003.
  • 2
    Bernards R, Weinberg RA: A progression puzzle. Nature 2002;418:823.
  • 3
    Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:34152.
  • 4
    Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:4954.
  • 5
    Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, Van Diest P, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003;63:567984.
  • 6
    Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjærde C, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 2007;1:16071.
  • 7
    Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:53749.
  • 8
    Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:51824.
  • 9
    Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, Van `t Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003;88:10914.
  • 10
    Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:44856.
  • 11
    Pfitzenmaier J, Ellis WJ, Hawley S, Arfman EW, Klein JR, Lange PH, et al. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 2007;25:21420.
  • 12
    Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:56372.
  • 13
    Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:815262.
  • 14
    Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007;53:5379.
  • 15
    Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HM, et al. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer 1981;44:8590.
  • 16
    Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Abou-Ghalia A, Cook M, et al. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 1996;5:5762.
  • 17
    Brooimans RA, De Leeuw N, Bontenbal M, Gratama JW. An immunomagnetic epithelial tumor cell enrichment model for minimal residual disease detection of cytokeratin 8+ malignancies. J Biol Regul Homeost Agents 2005;19:8491.
  • 18
    Molino A, Colombatti M, Bonetti F, Zardini M, Pasini F, Perini A, et al. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer 1991;67:10336.
  • 19
    Choesmel V, Pierga JY, Nos C, Vincent-Salomon A, Sigal-Zafrani B, Thiery JP, et al. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance. Breast Cancer Res 2004;6:R55670.
  • 20
    Pachmann K, Heiss P, Demel U, Tilz G. Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC). Clin Chem Lab Med 2001;39:8117.
  • 21
    Cai JY, Tang YJ, Jiang LM, Pan C, Chen J, Tang JY. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer 2007;49:9527.
  • 22
    Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Qvist H, et al. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 2004;10:30917.
  • 23
    Woelfle U, Breit E, Pantel K: Influence of immunomagnetic enrichment on gene expression of tumor cells. J Transl Med 2005;3:12.
  • 24
    Flatmark K, Bjornland K, Johannessen HO, Hegstad E, Rosales R, Harklau L, et al. Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 2002;8:4449.
  • 25
    Fodstad O, Faye R, Hoifodt HK, Skovlund E, Aamdal S. Immunobead-based detection and characterization of circulating tumor cells in melanoma patients. Recent Results Cancer Res 2001;158:4050.
  • 26
    Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793802.
  • 27
    Borgen E, Pantel K, Schlimok G, Muller P, Otte M, Renolen A, et al. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom 2006;70:4009.
  • 28
    Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006;107:88592.
  • 29
    Choesmel V, Anract P, Hoifodt H, Thiery JP, Blin N. A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases. Cancer 2004;101:693703.
  • 30
    Jung R, Soondrum K, Kruger W, Neumaier M. Detection of micrometastasis through tissue-specific gene expression: its promise and problems. Recent Results Cancer Res 2001;158:329.
  • 31
    Vlems FA, Diepstra JH, Cornelissen IM, Ruers TJ, Ligtenberg MJ, Punt CJ, et al. Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue. Mol Pathol 2002;55:15663.
  • 32
    Kruger WH, Jung R, Detlefsen B, Mumme S, Badbaran A, Brandner J, et al. Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells. Med Oncol 2001;18:338.
  • 33
    Raynor M, Stephenson SA, Walsh DC, Pittman KB, Dobrovic A: Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells. BMC Cancer 2002;2:14.
  • 34
    Sienel W, Mecklenburg I, Dango S, Ehrhardt P, Kirschbaum A, Passlick B, et al. Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer. Clin Cancer Res 2007;13:38407.
  • 35
    Soeth E, Grigoleit U, Moellmann B, Roder C, Schniewind B, Kremer B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol 2005;131:66976.
  • 36
    Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U, et al. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 1997;57:310610.
  • 37
    Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994;12:7259.
  • 38
    Fujita Y, Terashima M, Hoshino Y, Ohtani S, Kashimura S, Kanzaki N, et al. Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer. Gastric Cancer 2006;9:30814.
  • 39
    Ito H, Kanda T, Nishimaki T, Sato H, Nakagawa S, Hatakeyama K. Detection and quantification of circulating tumor cells in patients with esophageal cancer by real-time polymerase chain reaction. J Exp Clin Cancer Res 2004;23:45564.
  • 40
    Fortunato L, Baldi A, Farina M, Campioni M, Amini M, Piro FR, et al. Bone marrow and sentinel lymph node biopsy in patients with breast cancer: from staging to ultrastaging? J Exp Clin Cancer Res 2006;25:48793.
  • 41
    Natsugoe S, Nakashima S, Nakajo A, Matsumoto M, Okumura H, Tokuda K, et al. Bone marrow micrometastasis detected by RT-PCR in esophageal squamous cell carcinoma. Oncol Rep 2003;10:187983.
  • 42
    Inoue H, Kajiyama Y, Tsurumaru M. Clinicalsignificance of bone marrow micrometastases in esophageal cancer. Dis Esophagus 2004;17:32832.
  • 43
    Hoffmann K, Kerner C, Wilfert W, Mueller M, Thiery J, Hauss J, et al. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol 2007;13:25763.
  • 44
    Berois N, Varangot M, Sonora C, Zarantonelli L, Pressa C, Lavina R, et al. Detection of bone marrow-disseminated breast cancer cells using an RT-PCR assay of MUC5B mRNA. Int J Cancer 2003;103:5505.
  • 45
    Vlems FA, Diepstra JH, Cornelissen IM, Ligtenberg MJ, Wobbes T, Punt CJ, et al. Investigations for a multi-marker RT-PCR to improve sensitivity of disseminated tumor cell detection. Anticancer Res 2003;23:17986.
  • 46
    Slade MJ, Coombes RC. The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 2007;4:3041.
  • 47
    Varangot M, Barrios E, Sonora C, Aizen B, Pressa C, Estrugo R, et al. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer. Oncol Rep 2005;14:53745.
  • 48
    Alix-Panabieres C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005;299:17788.
  • 49
    Alix-Panabieres C, Rebillard X, Brouillet JP, Barbotte E, Iborra F, Segui B, et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem 2005;51:153841.
  • 50
    Molnar B, Sipos F, Galamb O, Tulassay Z. Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis 2003;21:3205.
  • 51
    Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review. J Surg Oncol 1998;67:194202.
  • 52
    Coello MC, Luketich JD, Litle VR, Godfrey TE. Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 2004;5:21425.
  • 53
    Morgan TM, Lange PH, Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 2007;12:30009.
  • 54
    Wolfrum F, Vogel I, Fandrich F, Kalthoff H. Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 2005;390:43041.
  • 55
    Jiao X, Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002;74:27884.
  • 56
    Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol 2007;107:3318.
  • 57
    Ghossein RA, Carusone L, Bhattacharya S. Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas. In Vivo 2000;14:23750.
  • 58
    Kollermann MW, Pantel K, Enzmann T, Feek U, Kollermann J, Kossiwakis M, et al. Supersensitive PSA-monitored neoadjuvant hormone treatment of clinically localized prostate cancer: effects on positive margins, tumor detection and epithelial cells in bone marrow. Eur Urol 1998;34:31824.
  • 59
    Braun S, Kentenich C, Janni W, Hepp F, De Waal J, Willgeroth F, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000;18:806.
  • 60
    Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:367885.
  • 61
    Weckermann D, Wawroschek F, Krawczak G, Haude KH, Harzmann R. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy? Urol Res 1999;27:28590.
  • 62
    Thorban S, Roder JD, Nekarda H, Funk A, Siewert JR, Pantel K. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst 1996;88:12227.
  • 63
    Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004;10:53428.
  • 64
    Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005;103:88491.
  • 65
    Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer 2005;114:94100.
  • 66
    Janni W, Wiedeswang G, Fehm T, Jueckstock J, Borgen E, Rack B, et al. Persistence of disseminated tumor cells in bone marrow of breast cancer patients predicts increased risk for relapse- results of pooled European data. J Clin Oncol 2006;24:146876.
  • 67
    Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006;103:173615.
  • 68
    Rack B, Janni W, Schoeberth A, Heinrigs M, Schindlbeck C, Strobl B, et al. Secundary adjuvant therapy with zoledronate in patients with early breast cancer: is there an effect on persisting isolated tumor cells in the bone marrow. Breast Cancer Res Treat 2004;88(S1):abstract 6019.
  • 69
    Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Kramer B, Vogel U, et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 2006;98:17984.
  • 70
    Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006;12:171520.
  • 71
    Kraemling M, Ruosaari S, Eijk P, Kaifi J, Hollmén J, Yekebas E, et al. Genomic profiles associated with early micrometastatic spread in lung cancer: relevance of 4q chromosomal aberrations. Cancer Res submitted.
  • 72
    Van't Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:5306.
  • 73
    Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G, et al. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer 1998;76:8248.
  • 74
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:165972.
  • 75
    Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995;1:10359.
  • 76
    Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005;8:22739.
  • 77
    Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:6839.
  • 78
    Gangnus R, Langer S, Breit E, Pantel K, Speicher MR. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 2004;10:345764.
  • 79
    Marches R, Scheuermann R, Uhr J. Cancer dormancy: from mice to man. Cell Cycle 2006;5:17728.
  • 80
    Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369:174257.
  • 81
    Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. Embo J 2003;22:421222.
  • 82
    Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006;6:4726.
  • 83
    Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:65660.
  • 84
    Coller HA, Sang L, Roberts JM: A new description of cellular quiescence. PLoS Biol 2006;4:e83.
  • 85
    Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006;12:561521.
  • 86
    Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis 2006;26:8798.
  • 87
    Felsher DW. Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle 2006;5:180811.
  • 88
    Indraccolo S, Favaro E, Amadori A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 2006;5:17515.
  • 89
    Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer 2006;6:1416.
  • 90
    Hedley BD, Allan AL, Chambers AF. Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. Future Oncol 2006;2:62741.
  • 91
    Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006;5:1799807.
  • 92
    White DE, Rayment JH, Muller WJ. Addressing the role of cell adhesion in tumor cell dormancy. Cell Cycle 2006;5:17569.
  • 93
    Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:23145.
  • 94
    Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 1998;95:148216.
  • 95
    Korah R, Boots M, Wieder R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004;64:451422.
  • 96
    Page K, Uhr JW. Mathematical models of cancer dormancy. Leuk Lymphoma 2005;46:31327.
  • 97
    Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:9037.
  • 98
    Melief CJ. Cancer: immune pact with the enemy. Nature 2007;450:8034.
  • 99
    Aguirre-Ghiso JA. The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 2006;5:17403.
  • 100
    Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:83446.
  • 101
    Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:1024.
  • 102
    Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:11127.
  • 103
    Pelengaris S, Abouna S, Cheung L, Ifandi V, Zervou S, Khan M: Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. BMC Biol 2004;2:26.
  • 104
    Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004;6:57786.
  • 105
    Weiss L. Metastatic inefficiency. Adv Cancer Res 1990;54:159211.
  • 106
    Rinker-Schaeffer CW, O'Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 2006;12:38829.
  • 107
    Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 2003;169:112233.
  • 108
    Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 2005;97:63242.
  • 109
    Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E, et al. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 2007;99:30921.
  • 110
    Steeg PS, Ouatas T, Halverson D, Palmieri D, Salerno M. Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 2003;4:5162.
  • 111
    Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:168495.
  • 112
    Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, Osborne CK, et al. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res 2001;61:23207.
  • 113
    Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:72132.
  • 114
    Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:177987.
  • 115
    Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:40110.
  • 116
    Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005;65:64937.
  • 117
    Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, et al. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 2005;308:24153.
  • 118
    Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 2002;99:224651.
  • 119
    Sung SY, Hsieh CL, Wu D, Chung LW, Johnstone PA. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 2007;31:36100.
  • 120
    Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006;66:166473.
  • 121
    Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, et al. Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am J Pathol 2006;168:140512.
  • 122
    Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89104.
  • 123
    Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1:44557.
  • 124
    Aguirre Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002;21:251324.
  • 125
    Heiss MM, Simon EH, Beyer BC, Gruetzner KU, Tarabichi A, Babic R, et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002;20:200516.
  • 126
    Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006;5:176071.
  • 127
    Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 2004;64:733645.
  • 128
    Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001;12:86379.
  • 129
    Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 2006;66:170211.
  • 130
    Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW: Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006;8:R16.
  • 131
    Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005;37:105562.
  • 132
    Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003;197:15768.
  • 133
    Weinhold KJ, Goldstein LT, Wheelock EF. The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. J Exp Med 1979;149:73244.
  • 134
    Matsuzawa A, Takeda Y, Narita M, Ozawa H. Survival of leukemic cells in a dormantstate following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (DL811). Int J Cancer 1991;49:3039.
  • 135
    Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E. Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. Adv Cancer Res 2007;97:189202.
  • 136
    Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, et al. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 1999;162:28429.
  • 137
    Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 2004;104:212433.
  • 138
    Klein CA, Holzel D. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 2006;5:178898.
  • 139
    Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 2007;4:699710.
  • 140
    Vessella RL, Pantel K, Mohla S. Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther 2007;6:1496504.
  • 141
    Naume B, Borgen E, Tossvik S, Pavlak N, Oates D, Nesland JM. Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method. Cytotherapy 2004;6:24452.
  • 142
    Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 2002;20:38792.
  • 143
    Kemming D, Meyer-Staeckling S, Alpers I, Brandt B. A real time PCR based assay for molecular characterization of disseminated tumor – a new tool for cancer diagnostics. GEN 2007;27(6).
  • 144
    Uhrig S, Schlembach D, Waldispuehl-Geigl J, Schaffer W, Geigl J, Klopocki E, et al. Impact of array comparative genomic hybridization-derived information on genetic counseling demonstrated by prenatal diagnosis of the TAR (thrombocytopenia-absent-radius) syndrome-associated microdeletion 1q21.1. Am J Hum Genet 2007;81:8668.
  • 145
    Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994;3:16573.
  • 146
    Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:32940.